Introduction
============

Central nervous system (CNS) infections can occur at any age and may be caused by a variety of pathogens, of which bacteria and fungi are the most prevalent ([@b1-etm-0-0-6312],[@b2-etm-0-0-6312]). With rising antibiotic resistance and various surgical operations, pathogens are adapting accordingly ([@b2-etm-0-0-6312]--[@b4-etm-0-0-6312]). Previous studies ([@b5-etm-0-0-6312]--[@b7-etm-0-0-6312]) have demonstrated that 8-10% of the regional population (including Egypt, Iran and China) has experienced bacterial and fungal infections of CNS, which expose patients to a higher risk of disability and mortality. Therefore, an accurate, more rapid etiologic identification is key to diagnosis and treatment. However, previous studies ([@b1-etm-0-0-6312],[@b2-etm-0-0-6312],[@b5-etm-0-0-6312],[@b1-etm-0-0-6312]) have reported that the majority of intracranial infections were not clearly diagnosed early enough during hospitalization, which may partially be attributed to limits of traditional detection methods. The conventional methods of cerebrospinal fluid (CSF) examination, including culture and microscopy, have a limited role in severe infections due to its low positive rate (8-20% in the majority of studies) and time-consuming process (2-7 days) ([@b6-etm-0-0-6312],[@b7-etm-0-0-6312],[@b9-etm-0-0-6312]--[@b11-etm-0-0-6312]). A number of novel etiological methods have been proposed as a supplement or substitute for the conventional technique, such as polymerase chain reaction (PCR), quantitative PCR ([@b5-etm-0-0-6312],[@b11-etm-0-0-6312]), multiplex PCR techniques ([@b3-etm-0-0-6312],[@b12-etm-0-0-6312]) and DNA sequencing based on 16S ribosomal DNA (16S rDNA) in bacteria or the internal transcribed spacer (ITS) in fungi ([@b6-etm-0-0-6312],[@b13-etm-0-0-6312]--[@b16-etm-0-0-6312]). To the best of our knowledge, PCR and multiplex PCR may only be effective for detecting common clinically suspected organisms ([@b3-etm-0-0-6312],[@b15-etm-0-0-6312]). Furthermore, using more primers will decrease the sensitivity and specificity ([@b15-etm-0-0-6312]). Finally, DNA sequencing of CSF in clinical application has been limited because of the high cost and low specificity associated with second-generation sequencing ([@b15-etm-0-0-6312],[@b17-etm-0-0-6312]).

Thus, a more rapid, broad-spectrum, accurate, and relatively inexpensive screening method that identifies pathogens from CSF is required. Previous studies ([@b18-etm-0-0-6312],[@b19-etm-0-0-6312]) have demonstrated the diagnostic value and importance of DNA microarray in the identification of viral CNS infections. This technology has been proposed to have the potential to simultaneously detect a large number of species with high specificity and has already resulted in its widespread adoption in clinical practice for the diagnosis of viral infections ([@b20-etm-0-0-6312]--[@b22-etm-0-0-6312]). However, previous studies have not examined if this technique can simultaneously detect bacterial and fungal CNS infections. The present study established two gene chips, containing 18 probes selected based on specific DNA sequence, to de bacterial and fungal CNS infections and to assess their clinical application value.

Materials and methods
=====================

### Clinical CSF samples and strains

A total of 88 CSF samples were collected from patients with suspected CNS infections and analyzed with DNA microarray from January 2014 to July 2016 at Xuanwu Hospital, Capital Medical University (Beijing, China). The present study was approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University. All patients provided written informed consent. The clinical diagnosis of CNS infection was based on the Harrison standard ([@b23-etm-0-0-6312]), combined with certain risk factors (CSF leak and surgery), clinical manifestations (fever and headache), and CSF examination results (white blood cell count, glucose and protein). The reference strains purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) were as follows: Streptococcus pneumoniae strain ATCC 49619, S. aureus strain ATCC 29213, E. coli strain ATCC 25922, Listeria monocytogenes strain ATCC 7644, Enterococcus faecalis strain ATCC 29212, K. pneumonia strain ATCC 700603, P. aeruginosa strain ATCC 27853, Enterobacter cloacae strain ATCC 700323, Haemophilus influenzae strain ATCC 49766, Cryptococcus neoformans strain ATCC 32269, Candida albicans strain ATCC 10231, Candida tropicalis strain ATCC 14058 and Candida glabrata strain ATCC 15126. The clinical isolates (Enterococcus faecium, A. baumannii, Stenotrophomonas maltophilia, coagulase negative staphylococcus, Neisseria meningitides, Burkholderia cepacia, Candida parapsilosis, Candida krusei, Cryptococcus gattii) used in the study were collected and identified by Vitek 2 Compact (bioMerieux SA, Marcy-l\'Étoile, France), Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS; Bruker Daltonics; Bruker Corporation, Billerica, MA, USA) and DNA sequencing ([@b24-etm-0-0-6312]).

### DNA extraction from strains and CSF

DNA of bacterial and fungal strains were extracted using Bacterial Genomic DNAiso kit (DP302; Tiangen Biotech Co., Ltd., Beijing, China) and Yeast DNAiso kit (DP307; Tiangen Biotech Co., Ltd., Beijing, China) according to the manufacturer\'s protocol. Each CSF sample (1-2 ml) was centrifuged at 12,000 × g for 5 min at room temperature (15-25°C). The supernatant was discarded and the sediment was pretreated using QIAamp UCP Pathogen Mini kit (Qiagen GmbH, Hilden, Germany), and DNeasy^®^ Blood & Tissue kit (Qiagen GmbH) was used to extract the sample DNA. The DNA was stored at −20°C.

### Primer design and PCR amplification

Based on a previous study ([@b15-etm-0-0-6312]), the bacterial and fungal universal primers, 16S rRNA and ITS, were designed to be capable of producing PCR products from standard strains and common organisms causing CNS infection as follows: 27F (forward, 5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492R (reverse, 5′-GGYTACCTTGTTACGACTT-3′), ITS1 (forward, 5′-GCCGTAGGTGAACCTGCGG-3′) and ITS4 (reverse, 5′-TCCTCCGCTTATTGATATGC-3′) were used for bacteria and fungi amplification, respectively. Other pairs of primers adding biotin were developed for amplification and hybridization as follows: B1 (forward, 5′-CCTACGGGAGGCAGCAG-3′) and B2 (reverse, 5′biotin-TACGGYTACCTTGTTACGACTT-3′; where Y is C or T), P1 (forward, 5′-CAATAAGCGGAGGAAAAGAAAC-3′) and P2 (reverse, 5′ biotin-ACTCCTTGGTCCGTGTTTCA-3′) were used for bacteria and fungi amplification, respectively. PCR was performed according to the protocol of a previous study ([@b15-etm-0-0-6312]) with a slight modification of annealing temperature of 56°C for 25 sec and extension of 72°C for 25 sec. The PCR products were analyzed using 1% agarose gel electrophoresis with ultraviolet gel imaging system (Syngene, Frederick, MD, USA), and the amplification bands of fungi and bacteria were observed.

### Synthesis of probes

The specific DNA sequences were screened for 14 types of bacteria and 4 fungi from GenBank (<http://www.ncbi.nlm.nih.gov/genbank/>), using the software Primer Premier 5.0 (Premier Biosoft International, Palo Alto, CA, USA) to design probes. The 16S universal probes as a positive reference for all bacteria were designed according to the sequences of conserved domain of 16S rDNA, and specific primers or probes were designed based on the sequence of variable domain of 16S rDNA. With the exceptions of E. coli and K. pneumonia, the genus probe was designed for other enterobacteria due to high homology. Each probe comprised a modified 19-33 amino acid sequence followed by a spacer of (Poly-dt)~16~ or (Poly-da)~16~ and a stretch of specific sequence ([Table I](#tI-etm-0-0-6312){ref-type="table"}). All primers and probes were synthesized by Shanghai Invitrogen Biotechnology; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The probe sequence was verified through the comparison of the probe sequence with the PCR product sequence in standard strains and clinical isolates.

### Microarray preparation and hybridization

Each array contained repeated triplicate identical sets of probes and arranged in a bacteria-specific matrix of 7×12 or fungi-specific matrix of 3×9 ([Fig. 1](#f1-etm-0-0-6312){ref-type="fig"}). Each matrix had 'landing-light' spots (spots of an internal control probe or a coordinate probe; Shanghai BaiO Technology Co., Ltd., Shanghai, China) made with cyanine 3 (Cy3)- or Cy5-labeled nucleotides to mark the array orientation. Following labeling the product, both control and sample DNAs were processed with a Hybrid chromogenic reagent kit (BST03021; Shanghai BaiO Technology Co., Ltd.) and hybridized using a BaiO^®^ e-Hyb Automatic hybrid instrument (BSE03011; Shanghai BaiO Technology Co., Ltd.) according to the manufacturers\' protocol. The hybridization temperatures of bacterial and fungal chips were 42 and 43°C, respectively, with each occurring for 30 min. Hybridization and color-substrate reaction procedures are listed in [Table II](#tII-etm-0-0-6312){ref-type="table"}.

The hybridized chip was scanned in BaiO^®^ BE-2.0 Biochip reading meter (BSE01011; Shanghai BaiO Technology Co., Ltd.). Image analysis, fluorescence signal intensity detection and quantification of each probe set was performed with BaiO^®^ Gene chip image analysis software V2.4 (Shanghai BaiO Technology Co., Ltd.). The identification of the infected specimens was determined, with ≥2 of the bacterial and fungal probes on the array displaying positive hybridization signals.

### Analytical sensitivity, specificity and reproducibility of microarray

The analytical sensitivity and specificity of the bacterial and fungal assay was calculated by analysis and comparison with the identified results of culture and sequencing method. A total of 18 clinical isolates (Stenotrophomonas maltophilia, Burkholderia cepacia and Candida parapsilosis; 6 isolates each) with no probes located in the chips, were used to analyze specificity. In addition, the following closely related type and reference strains were analyzed the analytical specificity of the assay: K. pneumoniae and E. coli, P. aeruginosa and Stenotrophomonas maltophilia, etc. Furthermore, genomic DNA of 2 types of pathogens with the sequenced isolates or reference strains were mixed and used as templates for testing the cross-reaction. The detection limit was determined with a 10-fold dilution series, ranging from 1 to 100,000,000 copies of the study strains. To test the reproducibility of the assay, all reference strains and sequenced clinical strains (S. aureus, E. coli and Cryptococcus neoformans) were analyzed and evaluated. DNA extraction, PCR amplification and gene chip hybridization experiment were repeated 6 times, in the same batch and different batches of microarrays. The clinical sensitivity, specificity, false-positive rate and false-negative rates of microarray technique were evaluated with clinical strains from 88 suspected infection CSF samples and 20 negative CSF samples.

### Statistical analysis

All data were analyzed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA), and the comparison of ratios expressed via the χ^2^ test or Fisher\'s exact test. P≤ was considered to indicate a statistically significant difference.

Results
=======

### PCR amplification and probe verification

The universal primers of bacteria and fungi were assessed by PCR and sequencing with standard strains and clinical isolates. The PCR products were confirmed to show clear bands of the appropriate size for fungi and bacteria (\~800 and 1,500 bp, respectively) on agarose gel electrophoresis ([Fig. 2](#f2-etm-0-0-6312){ref-type="fig"}). No bands were detected in the negative control and blank control (data not shown). The PCR products of the universal primers and DNA template from standard strains or clinical isolates were sequenced. The sequencing results are consistent with the sequences of bacteria or fungi from GenBank, thus confirming the efficiency and accuracy of designed primers. Furthermore, each probe matched that of the PCR products in all standard strains and clinical isolates.

### Microarray hybridization

A total of 13 standard strains and 15 clinical isolates were used to assess the chips. Coded DNA samples from species were randomly selected and hybridized to gene chips, with the typical and specific yellow fluorescent signals produced in corresponding microarray spots ([Figs. 3](#f3-etm-0-0-6312){ref-type="fig"} and [4](#f4-etm-0-0-6312){ref-type="fig"}). The results matched 98% of the results achieved by conventional detection methods except for some subspecies of coagulase negative Staphylococcus. The negative control displayed no signal.

### Assessment of microarray hybridization

The results of mixed hybridization revealed that the designed probes are able to detect a mix of 2 types of bacteria or 2 fungal isolates simultaneously ([Figs. 3Q and R](#f3-etm-0-0-6312){ref-type="fig"}, and [4F](#f4-etm-0-0-6312){ref-type="fig"}). Using bacterial products in the fungal microarray, no fluorescent signals were detected, and vice versa. No cross-reactions with bacterial species (K. pneumoniae and E. coli) tested and fungal species (Candida albicans and Candida tropicalis) tested by chips were detected. In the fixed condition of PCR, the minimum concentration of detection was 10 cfu ml^−1^ for Gram-negative bacteria, and 100 cfu ml^−1^ for Gram-positive bacterial and fungal species. The results also demonstrated that the fluorescent signals were directly associated with the concentration of bacterial and fungal suspension from 10-10,000 cfu ml^−1^. However, at the concentration ≥100,000 cfu ml^−1^, all pathogens exhibited the same strength of fluorescent signals. The result of reliability of gene chips with strains demonstrated that all the batch of gene chips reported the same identified results and the coefficient of variation (CV) for within-run and between-run assays were 5.0-8.0 and 5.0-7.0%, respectively, demonstrating both reproducibility and accuracy.

### Primary clinical application of the microarray

A total of 88 CSF samples from patients with suspected intracranial infections and 20 negative CSF samples were selected for microarray analysis. Culture testing took 4-7 days to complete the identification, whereas the microarray analysis took only 1 day. Culture testing presented 28 positive results (23 bacteria and 5 fungi), whereas the microarray analysis presented 41 positive cases of bacteria and fungi (35 bacteria and 6 fungi). The sensitivity of gene chip was higher than that of the culture method (100 vs. 68.3%, χ^2^=4.03, P\<0.05; [Table III](#tIII-etm-0-0-6312){ref-type="table"}). The results demonstrated that the specificity, false-positive rate and false-negative rate of microarray technique and culture method were 97.1 vs. 100%, 2.9 vs. 0%, and 0 vs. 31.7%, respectively.

A total of 13 extra pathogens that were determined negative using the culture method, were detected using the gene chip technique, including *P. aeruginosa* (n=2), *E. coli* (n=2), *Ochrobactrum anthropi* (n=2), *Streptococcus pneumonia* (n=1), *A. baumannii* (n=1), *Cryptococcus neoformans* (n=1), 16S positive (n=4). The 2 16S positive but unidentified strains were successfully sequenced and confirmed to be *Brucella spp*., but sequencing of the 2 other strains failed. Of the 13 cases, 2 patients were discharged from hospital prior to etiological diagnosis, 8 patients were treated accordingly based on DNA microarray analysis and recovered, but the 3 more serious cases infected with *Ochrobactrum anthropi, P. aeruginosa* and *A. baumannii* succumbed to encephalocele.

Discussion
==========

The rapid identification of bacteria and fungi can be achieved by the detection of characteristic bacterial genes and fungal genes in CSF specimens, which is important for clinical diagnosis and therapy. Certain non-culture methods have been developed to detect pathogens from CSF samples and may be more sensitive than conventional methods. Previous studies ([@b6-etm-0-0-6312],[@b13-etm-0-0-6312]--[@b16-etm-0-0-6312]) have usually chosen the 16S rRNA and ITS as a target for universal primers to amplify bacteria and fungi, respectively. The 16S rRNA is composed of conserved regions and variable regions, which are widely used in classification and identification of bacteria ([@b14-etm-0-0-6312]--[@b16-etm-0-0-6312]). The conserved region and variable region provide the premise for the design of bacterial species-specific primers and probes. In addition, detection of variations of ITS within fungal rDNA spacer regions has been demonstrated to be effective for the identification and classification of fungi ([@b19-etm-0-0-6312]). The microarray-based virus detection provides a diagnostic tool for viral CNS infections ([@b3-etm-0-0-6312]). As such, the two technologies of universal primers PCR and DNA microarray were combined in the present study to detect 14 types of bacteria and 4 fungi. The detection was performed in 1 day, facilitating the rapid detection of pathogens causing CNS infection.

The diagnostic probes designed in the microarray covered \>95% of the bacterial and fungal pathogens responsible for intracranial infection. The DNA microarray exhibited positive fluorescence at the corresponding sites when validating the array with standard strains, except for certain subspecies of coagulase negative Staphylococcus, which exhibited negative signals, possibly because a single probe of coagulase negative Staphylococcus cannot completely detect all subspecies. In our future study, more probes will be designed to detect these subspecies.

The minimum concentration of detection of chips, serving a key role in positive rate, was analyzed in the present study. The results demonstrated that the gene chips were able to identify pathogens at a concentration of 10 cfu ml^−1^ (10 µl/well) for bacteria and 100 cfu ml^−1^ (10 µl/well) for fungi. In contrast, PCR sequencing was only able to identify pathogens accurately at \>10,000 cfu ml^−1^ (10 µl/well). Hence, DNA microarray is more sensitive in the detection of all bacteria and fungi, and even more sensitive for detection of Gram-negative bacteria than PCR sequencing. A possible explanation is that Gram-positive bacteria and fungi cell membranes are notoriously difficult to break ([@b13-etm-0-0-6312],[@b19-etm-0-0-6312]), which may lead to poor DNA extraction. The results are notable as the low detection limit will allow direct detection of the DNA from patient specimens, thus improving the detection rate. Furthermore, the results demonstrated that the hybridization signal was linearly dependent on the concentration of targeted microbes. This potentially makes it possible for quantification and automation in the future. The results demonstrated that every probe was specific for its corresponding pathogen, and there was no cross-reaction between them, indicating high specificity in the microarray technique. The results of reproducibility demonstrated that the repeatability of detection using chips had a high CV (5.0-8.0%). However, the reproducibility was tested with purified DNA and simulated specimens instead of real clinical samples in the present study, therefore the latter may have issues of incomplete DNA isolation, inhibitors being present, etc. which may affect sensitivity.

The rate of false-positive results of microarray technique was 2.9%, which may be due to the contamination of samples. Effective methods for the removal of these substances will be developed and the present protocol will be modified with rigorous use of controls, including the extraction protocol, PCR amplification, hybridization steps and analysis of fluorescence signals.

A total of 23 cases of bacterial and 5 cases of fungal positive culture specimens were identified to have the same results using the microarray assay. A further 12 bacterial and 1 fungal cases of culture-negative specimen were identified, 9 were identified using gene chip hybridization technique, demonstrating the presence of infection. This suggests that microarray technology may be more sensitive than conventional CSF culture methods, which is consistent with other findings ([@b3-etm-0-0-6312],[@b6-etm-0-0-6312]). The 4 unidentified strains that were demonstrated to be positive only in the universal probe sites (16S), which may be due to the pathogens not belonging to any of the species included in the study design. The 2 16S positive unidentified strains were successfully sequenced and confirmed to be *Brucella spp*., and the infection was controlled with accordingly antimicrobial agents and recovered. Of the 13 cases, 10 patients were recovering and discharged, indicating a higher clinical diagnostic value. The availability of species identification by use of this rapid and sensitive method will enable physicians to treat with appropriate antimicrobial agents in the absence of positive-culture in the CSF in a timely manner, and in turn reduce the inappropriate use of antibiotics and improve patient management.

Based on these findings, the DNA microarray assay of the present study is suitable for detecting and analyzing a large number of pathogens simultaneously, which may facilitate detection and identification of the pathogens responsible for serious infection, especially in the initial screening of patients with suspected CNS infections. Although DNA microarray is not currently the widely accepted clinical diagnostic method, previous studies ([@b12-etm-0-0-6312],[@b20-etm-0-0-6312],[@b22-etm-0-0-6312]) and the present study have demonstrated the potential clinical application value of DNA microarray due to its high sensitivity, specificity and reproducibility, while also being less time-consuming. The DNA microarray can also be proposed as a valuable supplement or substitute for the traditional methods (microscopy and culture) in clinical diagnosis of intracranial infections. Furthermore, this method can simultaneously detect a large number of pathogens, suggesting that this technique is helpful in the initial screening of patients with suspected CNS infections. However, the present study was limited by the single-center design and the small number of patients. To improve the clinical value and application of DNA microarray for CNS infections, multi-center large-sample studies with standardized diagnostic criteria and procedures will be conducted in the future. Studies are currently under way to increase the range of species, add ≥2 more probes for each species that can be identified and to apply the small chip directly to CSF specimens and other clinical specimens.

The findings of the present study suggest that high-density probe of the assay can greatly enhance detection range of species and reduce the cost of testing. Furthermore, it is vital to conduct comprehensive analysis in the future to avoid false-positive results caused by contamination and false-negative results caused by improper DNA extraction methods.
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![The probe site arrangement of the bacteria and fungi gene-detecting chips. (A) Fungi: 1, *Candida albicans*; 2, *Candida tropicalis*; 3, *Candida glabrata*; 4, *Cryptococcus neoformans*; 5, ITS; and 6, blank control. (B) Bacteria: 1, *Klebsiella pneumoniae*; 2, *Acinetobacter baumannii*; 3, *Pseudomonas aeruginosa*; 4, *Escherichia coli*; 5, enterobacter; 6, *Haemophilus influenzae*; 7, *Stenotrophomonas maltophilia*; 8, *Neisseria meningitidis*; 9, *Enterococcus faecalis*; 10, *Enterococcus faecium*; 11, *Listeria monocytogenes*; 12, *Staphylococcus aureus*; 13, *Streptococcus pneumoniae*; 14, Coagulase negative staphylococci; 15, blank control; 16, Gram-negative bacteria; 17, Gram-negative bacteria; 18, 16S; 19, experimental water; 0, internal control probes.](etm-16-02-1304-g00){#f1-etm-0-0-6312}

![Detection of bacterial and fungal strains using electrophoresis of the polymerase chain reaction products. Lane 1, *Escherichia coli*; lane 2, *Candida albicans*; lane 3, *Staphylococcus aureus*; lane 4, *Candida tropicalis*; lane 5, *Enterococcus faecalis*; lane 6, *Candida glabrata*; lane 7, *Klebsiella pneumoniae*; lane 8, *Cryptococcus neoformans*; lane 9, *Pseudomonas aeruginosa*; lane 10, negative control; lane 11, *Enterobacter cloacae*; M, DNA marker.](etm-16-02-1304-g01){#f2-etm-0-0-6312}

![The identification results of bacterial species using DNA microarray. (A) *Klebsiella pneumonia*; (B) *Acinetobacter baumannii*; (C) *Pseudomonas aeruginosa*; (D) *Escherichia coli*; (E) *Enterobacter cloacae*; (F) *Haemophilus influenzae*; (G) *Stenotrophomonas maltophilia*; (H) gram-positive bacteria; (I) *Enterococcus faecalis*; (J) *Enterococcus faecium*; (K) *Listeria monocytogenes*; (L) *Staphylococcus aureus*; (M) *Streptococcus pneumonia*; (N) gram-negative bacteria; (O) *Staphylococcus homis*; (P) *Neisseria meningitidis*; (Q) *Klebsiella pneumonia* and *Enterobacter cloacae*; (R) *Enterococcus faecium* and *Escherichia coli*.](etm-16-02-1304-g02){#f3-etm-0-0-6312}

![The identification results of fungal species using DNA microarray. (A) *Candida albicans*; (B) *Candida tropicalis*; (C) *Candida glabrata*; (D) *Cryptococcus neoformans*; (E) *Candida parapsilosis*; (F) *Candida albicans* and *Candida glabrata*.](etm-16-02-1304-g03){#f4-etm-0-0-6312}

###### 

Sequences of microarray hybridization probes for bacteria and fungi.

  No. of spot   Name                                Probe sequence (5′-3′)
  ------------- ----------------------------------- -------------------------------------------------------
  Bacteria                                          
    1           *Klebsiella pneumonia*              NH2-ttttttttttttttttAGCTAATACCGCATAATGTCGCAAGACCAAAGT
    2           *Acinetobacter baumannii*           NH2-ttttttttttttttttCGGTCGCAAGACTAAAACTCAA
    3           *Pseudomonas aeruginosa*            NH2-ttttttttttttttttCCAAAAGCTACTGAGCTAGAGTACGGTA
    4           *Escherichia coli*                  NH2-ttttttttttttttttCGGTTTGTTAAGTCAGATGTG
    5           *Enterobacter spp*.                 NH2-ttttttttttttttttCGGGGAGGAAGGTGTTGTGGTTAAT
    6           *Haemophilus influenzae*            NH2-ttttttttttttttttGATGTGTTAATAGCACATCAAATTGACGTT
    7           *Stenotrophomonas maltophilia*      NH2-ttttttttttttttttCGCTAATACCGCATACGACCTACGGGTGAAAGC
    8           *Neisseria meningitidis*            NH2-ttttttttttttttttCAACCTGATTGCTTGGTAGCGTAG
    9           *Enterococcus faecalis*             NH2-ttttttttttttttttCGTTAGTAACTGAACGTCCCCTG
    10          *Enterococcus faecium*              NH2-ttttttttttttttttATGCAAGTCGAACGCTTCTTTTTCCACCGG
    11          *Listeria monocytogenes*            NH2-ttttttttttttttttAGAACAAGGATAAGAGTAACTGC
    12          *Staphylococcus. aureus*            NH2-ttttttttttttttttAGAACATATGTGTAAGTAACTGTGCACATC
    13          *Streptococcus. pneumoniae*         NH2-ttttttttttttttttAGAAGAACGAGTGTGAGAGTGGAAAGTTCAC
    14          Coagulase negative staphylococcus   NH2-ttttttttttttttttGATGAAGGTCTTCGGATCGTAAAACTCTGTTAT
    15          Blank control                       --
    16          Gram-negative                       NH2-ttttttttttttttttCTGATGCAGCCGCGTGTGTGAAG
    17          Gram-positive                       NH2-ttttttttttttttttGATGACGTCAAATCATCATGCCCCTTATG
    18          Bacterial Universal probe           NH2-ttttttttttttttttAACAGGATTAGATACCCTGGTAGTCCA
    19          Negative control                    NH2-ttttttttttttttttATTTGTCTTTGTAGATCTTCCCT
  Fungi                                             
    1           *Candida albicans*                  NH2-ttttttttttttttttGCATGCTGCTCTCTCGGG
    2           *Candida tropicalis*                NH2-ttttttttttttttttACTGGCTCTTTCAGAGTCCGA
    3           *Candida glabrata*                  NH2-ttttttttttttttttACTGGTACCTTTGGTGCCCGA
    4           *Cryptococcus neoformans*           NH2-ttttttttttttttttTGACACGATCACCAGTGCTC
    5           Fungal universal probe              NH2-aaaaaaaaaaaaaaaaTGGGTGGTAAATTCCATCTAAAGC
    6           Blank control                       --

###### 

Protocols of bacterial and fungal chip hybridization.

  Procedure   Reagent                     Volume (µl)   Time (min)   Sampling times   Temperature (°C)
  ----------- --------------------------- ------------- ------------ ---------------- ------------------
  1           Prehybridization solution   1,200         5            1                42,43
  2           Hybridization solution        200         30           1                42,43
  3           Wash solution1                800         6            2                42,43
  4           Wash solution2              1,600         5            2                28
  5           Antibody solution             200         20           1                28
  6           Wash solution2              /             5            2                28
  7           Wash solution3                400         3            1                28
  8           Color-substrate solution      200         20           1                42,43
  9           Prehybridization solution   /             2            2                28

All reagents listed were provided as part of the BaiO^®^ e-Hyb Automatic hybrid instrument kit (Shanghai BaiO Technology Co., Ltd., Shanghai, China). 42,43°C represents the hybridization temperatures of bacteria and fungal chips, respectively.

###### 

Positive rates of pathogen detected with DNA microarray and culture method in cerebrospinal fluid.

                         DNA microarray   Culture                                
  ---------------------- ---------------- --------- ---- ---- ---- --- ---- ---- --------
  Study group (n=88)     35               6         33   14   23   5   45   15   \<0.05
  Control group (n=20)   0                0         10   10   0    0   10   10   \>0.05
  Total (n=108)          35               6         43   24   23   5   55   25   

DNA sequencing was performed for each sample.
